Compugen (CGEN) Q2 FY26 earnings call

Compugen reported steady progress across its clinical pipeline and partnerships in Q2 FY26, highlighted by the MAIA-ovarian trial advancing towards interim analysis and AstraZeneca's continued investment in rilvogostamig with new Phase III trials and positive ASCO data. The company maintains a strong financial position with a cash runway into 2029, supporting ongoing clinical development and early-stage discovery efforts. While the placebo arm PFS estimate for MAIA-ovarian was adjusted, management remains confident in the trial's design and potential for clear clinical conclusions.